Home > Publications Database > Associations of inferior frontal sulcal hyperintensities on brain MRI with cerebral small vessel disease, cognitive function, and depression symptoms. > print

001     276183
005     20250205165933.0
024 7 _ |a 10.1038/s41598-025-87493-8
|2 doi
024 7 _ |a pmid:39849098
|2 pmid
037 _ _ |a DZNE-2025-00251
041 _ _ |a English
082 _ _ |a 600
100 1 _ |a Dörner, Marc
|0 P:(DE-2719)9002951
|b 0
|e First author
|u dzne
245 _ _ |a Associations of inferior frontal sulcal hyperintensities on brain MRI with cerebral small vessel disease, cognitive function, and depression symptoms.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1738751443_16422
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Inferior frontal sulcal hyperintensities (IFSH) observed on fluid-attenuated inversion recovery (FLAIR) MRI have been proposed as indicators of elevated cerebrospinal fluid waste accumulation in cerebral small vessel disease (CSVD). However, to validate IFSH as a reliable imaging biomarker, further replication studies are required. The objective of this study was to investigate associations between IFSH and CSVD, and their potential repercussions, i.e., cognitive impairment and depression. We prospectively recruited 47 patients with CSVD and 29 cognitively normal controls (NC). IFSH were rated visually based on FLAIR MRI. Using different regression models, we explored the relationship between IFSH, group status (CSVD vs. NC), CSVD severity assessed with MRI, cognitive function, and symptoms of depression. Patients with CSVD were more likely to have higher IFSH scores compared to NC (OR 5.64, 95% CI 1.91-16.60), and greater CSVD severity on MRI predicted more severe IFSH (OR 1.47, 95% CI 1.14-1.88). Higher IFSH scores were associated with lower cognitive function (-0.96, 95% CI -1.81 to -0.10), and higher levels of depression (0.33, 95% CI 0.01-0.65). CSVD and IFSH may be tightly linked to each other, and the accumulation of waste products, indicated by IFSH, could have detrimental effects on cognitive function and symptoms of depression.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Cerebral amyloid angiopathy
|2 Other
650 _ 7 |a Cerebral small vessel disease
|2 Other
650 _ 7 |a Fluid-attenuated inversion recovery
|2 Other
650 _ 7 |a Glymphatic system
|2 Other
650 _ 7 |a Hypertensive arteriopathy
|2 Other
650 _ 7 |a Inferior frontal sulcal hyperintensity
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cerebral Small Vessel Diseases: diagnostic imaging
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging: methods
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Depression: diagnostic imaging
|2 MeSH
650 _ 2 |a Cognition: physiology
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnostic imaging
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Frontal Lobe: diagnostic imaging
|2 MeSH
650 _ 2 |a Frontal Lobe: pathology
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
700 1 _ |a Pfister, Malte
|b 1
700 1 _ |a Tyndall, Anthony
|b 2
700 1 _ |a von Känel, Roland
|b 3
700 1 _ |a Neumann, Katja
|0 P:(DE-2719)2810407
|b 4
|u dzne
700 1 _ |a Schreiber, Frank
|0 P:(DE-2719)9000986
|b 5
|u dzne
700 1 _ |a Arndt, Philipp
|0 P:(DE-2719)9000797
|b 6
|u dzne
700 1 _ |a Fuchs, Erelle
|b 7
700 1 _ |a Garz, Cornelia
|0 P:(DE-2719)2813207
|b 8
|u dzne
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 9
|u dzne
700 1 _ |a Butryn, Michaela
|0 P:(DE-2719)9001011
|b 10
|u dzne
700 1 _ |a John, Anna-Charlotte
|b 11
700 1 _ |a Hildebrand, Annkatrin
|b 12
700 1 _ |a Euler, Sebastian
|b 13
700 1 _ |a Hofmann, Andreas B
|b 14
700 1 _ |a Machetanz, Lena
|b 15
700 1 _ |a Kirchebner, Johannes
|b 16
700 1 _ |a Tacik, Pawel
|0 P:(DE-2719)9002214
|b 17
|u dzne
700 1 _ |a Grimm, Alexander
|b 18
700 1 _ |a Jansen, Robin
|b 19
700 1 _ |a Pawlitzki, Marc
|b 20
700 1 _ |a Henneicke, Solveig
|0 P:(DE-2719)2813348
|b 21
|u dzne
700 1 _ |a Perosa, Valentina
|b 22
700 1 _ |a Labeit, Bendix
|b 23
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 24
|u dzne
700 1 _ |a Meuth, Sven G
|b 25
700 1 _ |a Vielhaber, Stefan
|0 P:(DE-2719)2000035
|b 26
|u dzne
700 1 _ |a Mattern, Hendrik
|0 P:(DE-2719)9002178
|b 27
|u dzne
700 1 _ |a Bernal, Jose
|0 P:(DE-2719)9001989
|b 28
|e Last author
|u dzne
700 1 _ |a Schreiber, Stefanie
|0 P:(DE-2719)2812631
|b 29
|e Last author
|u dzne
773 _ _ |a 10.1038/s41598-025-87493-8
|g Vol. 15, no. 1, p. 2999
|0 PERI:(DE-600)2615211-3
|n 1
|p 2999
|t Scientific reports
|v 15
|y 2025
|x 2045-2322
856 4 _ |u https://pub.dzne.de/record/276183/files/DZNE-2025-00251%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/276183/files/DZNE-2025-00251.pdf
856 4 _ |u https://pub.dzne.de/record/276183/files/DZNE-2025-00251%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/276183/files/DZNE-2025-00251%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/276183/files/DZNE-2025-00251%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/276183/files/DZNE-2025-00251.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:276183
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002951
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)2810407
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9000986
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9000797
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2813207
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2811614
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9001011
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)9002214
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)2813348
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2000005
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 26
|6 P:(DE-2719)2000035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)9002178
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)9001989
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2812631
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2024-12-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-07-29T15:28:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-07-29T15:28:26Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
920 1 _ |0 I:(DE-2719)1310010
|k AG Schreiber
|l Mixed Cerebral Pathologies and Cognitive Aging
|x 0
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 1
920 1 _ |0 I:(DE-2719)1011103
|k AG Spottke
|l Clinical Research Platform (CRP)
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1310010
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1011103
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21